Merck KGaA Email Format

Pharmaceutical Manufacturing
50,001-100,000 employees
Darmstadt, Germany

Merck KGaA is a German multinational science and technology company operating in life science, healthcare, and electronics sectors with a global presence spanning over 350 years.

Find contacts at Merck KGaA

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@merckgroup.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
1668
Headquarters
Darmstadt, Germany
Revenue
$5B-$10B
FUNDING Stage
Public
Key Executives
Kai Beckmann (Chairman of the Executive Board and Group CEO), Helene von Roeder (Member of the Executive Board | Chief Financial Officer), Laura Matz (Chief Science and Technology Officer)

Tech Stack

Google Cloud

Cloud

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Merck KGaA?

Merck KGaA uses the first.last format, so Jane Smith would be jane.smith@merckgroup.com.

What are the three business segments that Merck KGaA operates across?

Merck KGaA operates across three business segments: Life Science, Healthcare, and Electronics. Life Science covers research tools and bioprocessing, Healthcare spans oncology, neurology, and rare diseases, and Electronics supplies materials for semiconductor and display manufacturing.

How does Merck KGaA's Life Science Process Solutions unit serve pharmaceutical and biotech companies?

Merck KGaA's Process Solutions business helps pharmaceutical and biotech companies develop, manufacture, purify, formulate, and assure the quality of drugs and biologics. It covers single-use manufacturing, filtration, chromatography, and purification at every stage of drug production. Tools like Clay can help you identify and reach the right contacts within this division.

Which rare disease therapy did Merck KGaA gain from its 2025 acquisition of SpringWorks Therapeutics?

Merck KGaA completed its acquisition of SpringWorks Therapeutics in July 2025, adding Ogsiveo (nirogacestat) to its rare disease portfolio. Ogsiveo is an FDA-approved oral therapy for adults with progressing desmoid tumors and received European Commission approval in August 2025.

Where is Merck KGaA's largest semiconductor materials production campus located?

Merck KGaA inaugurated its largest semiconductor materials campus worldwide in Kaohsiung, Taiwan in late 2025, representing a total investment of 500 million euros. The 150,000 square meter site began production in 2026 and supports the company's Electronics segment semiconductor materials supply chain.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles